ARTICLE | Clinical News
Cylexin CY-1503: Began Phase II trial
December 19, 1994 8:00 AM UTC
Cytel Corp. (CYTL), San Diego Product: Cylexin CY-1503 small carbohydrate blocker of cell adhesion in inflammation Indication: Prevent reperfusion injury in heart attack patients undergoing angioplast...